



## **United States Patent and Trademark Office**

COMMISSIONER OF PATENTS AND TRADEMARKS Address:

Washington, D.C. 20231

SELITTO.

FILING DATE

BEHR

FIRST NAMED INVENTOR

ATTORNEY DOCKET NO.

HM11/0827

F.C.

**EXAMINER** 

P.O. BOX 1477

100 PLAINFIELD

EDISON NJ 08818

**AVENUE** 

KIM,

**ART UNIT** 

PAPER NUMBER

DATE MAILED:

08/27/01.

AUG 2 9 2001 SELITTO, BEHR &

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

STATES DEPARTMENT OF COMMERCE and Trademark Office COMMISSIONER OF PATENTS AND TRADEMAR Washington, D.C. 20231

SERIAL NUMBER FILING DATE		FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.	
09 547,215 4/11/00	Schally			
r				
			EXAMINER	
		F.T. MOEZIE		
		ART UNIT	PAPER NUMBER	
		1653	4	

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

DATE MAILED:

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Note: Upon compliance with the requirements applicant must also amend the application to provide the SEQ ID NOS in THE SPECIFICATION (at least in the first occurance), in ALL EXAMPLES, TABLES and THE CLAIMS.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for response beyond the SIX MONTH statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to F.T. MOEZIE whose telephone number is (703) 305-4508 or Dr. LOW (5 PE) at 308-2923.

1653

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirement for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):	S
1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).	٠
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.82	:1(e)
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."	
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must submitted as required by 37 CFR 1.825(d).	)e
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing as required by 37 CFR 1.821(e).	g"
7. Other: ————————————————————————————————————	_
Applicant must provide:	
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"	
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification	
A statement that the content of the paper and computer readable copies are the same and, where applicable, include new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)	no
For questions regarding compliance with these requirements, please contact:	
or Rules Interpretation, call (703) 308-1123	

Please return a copy of this notice with your response.

For CRF submission help, call (703) 308-4212 For Patentin software help, call (703) 308-6856

FH